Equities research analysts expect that Acutus Medical, Inc. (NASDAQ:AFIB) will report ($0.70) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Acutus Medical’s earnings, with estimates ranging from ($0.95) to ($0.26). The business is expected to report its next earnings report on Thursday, June 17th.
According to Zacks, analysts expect that Acutus Medical will report full year earnings of ($2.74) per share for the current financial year, with EPS estimates ranging from ($3.48) to ($1.27). For the next year, analysts forecast that the business will report earnings of ($2.18) per share, with EPS estimates ranging from ($3.10) to ($0.98). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Acutus Medical.
Acutus Medical (NASDAQ:AFIB) last announced its quarterly earnings data on Wednesday, March 17th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.33). The firm had revenue of $2.57 million for the quarter, compared to analysts’ expectations of $2.52 million.
A number of hedge funds have recently modified their holdings of AFIB. Deerfield Management Company L.P. Series C bought a new stake in Acutus Medical in the 3rd quarter worth about $129,386,000. BlackRock Inc. bought a new stake in Acutus Medical in the 3rd quarter worth about $20,263,000. Bamco Inc. NY grew its position in Acutus Medical by 60.3% in the 4th quarter. Bamco Inc. NY now owns 465,000 shares of the company’s stock worth $13,397,000 after purchasing an additional 175,000 shares in the last quarter. State Street Corp bought a new stake in Acutus Medical in the 3rd quarter worth about $3,589,000. Finally, Nicholas Investment Partners LP grew its position in Acutus Medical by 32.7% in the 4th quarter. Nicholas Investment Partners LP now owns 425,415 shares of the company’s stock worth $12,256,000 after purchasing an additional 104,788 shares in the last quarter. 69.56% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ AFIB traded down $0.09 during trading on Friday, hitting $13.25. 4,725 shares of the company traded hands, compared to its average volume of 377,570. The business’s fifty day moving average is $17.58 and its 200 day moving average is $24.90. Acutus Medical has a fifty-two week low of $12.59 and a fifty-two week high of $38.99. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.89 and a quick ratio of 10.21.
About Acutus Medical
Acutus Medical, Inc, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs.
Read More: retirement calculator
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.